严重酒精相关性肝炎伴既往肝失代偿史患者的早期肝移植
研究纳入6个美国中心2007至2020年间241例因临床诊断酒精相关性肝炎接受早期肝移植的连续患者,比较首次肝失代偿与既往肝失代偿者的移植后结局。既往肝失代偿与移植后死亡风险升高(调整后HR 2.72,95%CI 1.61-4.59)及有害饮酒风险升高(调整后HR 1.77,95%CI 1.07-2.94)相关。作者认为既往肝失代偿是风险因素但非绝对禁忌证,需更大规模研究完善该标准。
要点
- 既往肝失代偿者移植后调整死亡风险升高(调整后HR 2.72,95%CI 1.61-4.59)。
- 既往肝失代偿者移植后有害饮酒风险升高(调整后HR 1.77,95%CI 1.07-2.94)。
- 既往肝失代偿者3年生存率仍达78%(95%CI 57%-89%),作者认为提示早期肝移植存在生存获益。
核心结论
- 既往肝失代偿与早期肝移植后死亡风险升高及有害饮酒风险升高相关。
- 作者认为该结果是初步安全性信号,并验证首次肝失代偿可作为考虑早期肝移植的标准。
- 作者认为3年生存率较高提示早期肝移植存在生存获益,且需更大规模研究完善该标准。
- 作者认为既往肝失代偿是风险因素,但非早期肝移植的绝对禁忌证。
研究设计与样本
- 研究纳入6个美国早期肝移植酒精相关性肝炎联盟中心的连续病例,为2007年至2020年间因临床诊断酒精相关性肝炎接受早期肝移植的患者。
- 共纳入241例肝移植受者,其中首次肝失代偿210例,既往肝失代偿31例。
- 既往肝失代偿定义为腹水、肝性脑病、静脉曲张出血或黄疸的诊断,且该事件后仍有饮酒证据。
- 采用调整Cox回归评估首次与既往肝失代偿与移植后死亡率及有害饮酒的关联。
主要发现
- 首次与既往肝失代偿组中位年龄分别为43岁与38岁(P=0.23),终末期肝病模型钠评分均为39分(P=0.98),移植后随访时间分别为2.3年与1.7年(P=0.08)。
- 首次与既往肝失代偿组未调整1年生存率分别为93%(95%CI 89%-96%)与86%(95%CI 66%-94%),3年生存率分别为85%(95%CI 79%-90%)与78%(95%CI 57%-89%)。
- 既往肝失代偿与移植后调整死亡风险升高相关(调整后HR 2.72,95%CI 1.61-4.59)。
- 既往肝失代偿与移植后有害饮酒风险升高相关(调整后HR 1.77,95%CI 1.07-2.94)。
临床怎么用
- 作者认为既往肝失代偿是早期肝移植的风险因素,但非绝对禁忌证。
- 作者认为首次肝失代偿可作为考虑早期肝移植的标准,但需更大规模研究完善该标准。
局限性
- 作者称该结果为初步安全性信号。
- 作者指出需更大规模研究来完善该标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the published studies of early liver transplantation (LT) for alcohol-associated hepatitis (AH), patients with a prior liver decompensation are excluded. The appropriateness of this criteria is unknown. METHODS: Among 6 American Consortium of Early Liver Transplantation for Alcohol-Associated Hepatitis sites, we included consecutive early LT for clinically diagnosed AH between 2007 and 2020. Patients were stratified as first vs prior history of liver decompensation, with the latter defined as a diagnosis of ascites, hepatic encephalopathy, variceal bleeding, or jaundice, and evidence of alcohol use after this event. Adjusted Cox regression assessed the association of first (vs prior) decompensation with post-LT mortality and harmful (i.e., any binge and/or frequent) alcohol use. RESULTS: A total of 241 LT recipients (210 first vs 31 prior decompensation) were included: median age 43 vs 38 years ( P = 0.23), Model for End-Stage Liver Disease Sodium score of 39 vs 39 ( P = 0.98), and follow-up after LT 2.3 vs 1.7 years ( P = 0.08). Unadjusted 1- and 3-year survival among first vs prior decompensation was 93% (95% confidence interval [CI] 89%-96%) vs 86% (95% CI 66%-94%) and 85% (95% CI 79%-90%) vs 78% (95% CI 57%-89%). Prior (vs first) decompensation was associated with higher adjusted post-LT mortality (adjusted hazard ratio 2.72, 95% CI 1.61-4.59) and harmful alcohol use (adjusted hazard ratio 1.77, 95% CI 1.07-2.94). DISCUSSION: Prior liver decompensation was associated with higher risk of post-LT mortality and harmful alcohol use. These results are a preliminary safety signal and validate first decompensation as a criterion for consideration in early LT for AH patients. However, the high 3-year survival suggests a survival benefit for early LT and the need for larger studies to refine this criterion. These results suggest that prior liver decompensation is a risk factor, but not an absolute contraindication to early LT.
引用
- Weinberg EM, Dukewich M, Jakhete N, et al. Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation. Am J Gastroenterol. 2022. PMID: 35853462. doi:10.14309/ajg.0000000000001901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。